- Home
- KIO vs NMRA Comparison
KIO vs NMRA Comparison
Compare KIO & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KIO | NMRA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | 2400 | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.6M | 424.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | KIO | NMRA |
|---|---|---|
| Price | $11.56 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 136.5K | ★ 970.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $0.61 |
| 52 Week High | $13.59 | $11.57 |
Technical Indicators
Market Signals| Indicator | KIO | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 39.73 |
| Support Level | $11.67 | $2.05 |
| Resistance Level | $11.65 | $2.36 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 39.29 | 15.32 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.